F

Fundacao Champalimaud | Centro Clinico Champalimaud - Unidade Investigacao Clinica

Research site
(Unclaimed)
Location
Avenida Brasilia s/n, Lisbon, Lisbon, Portugal
Site insights

Top conditions

Urinary Bladder Cancer (2 trials)

Lung Cancer (2 trials)

Breast Cancer (1 trial)

Lymphoma (1 trial)

Non-Small-Cell Lung Carcinoma (1 trial)

Top treatments

TAR-200
Gemcitabine
9-ING-41
Dexamethasone
Pomalidomide
Sacituzumab
Cisplatin
Cetrelimab
Bortezomib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

4 of 5
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
9-ING-41 in Patients With Advanced Cancers

GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and e...

Active, not recruiting
Neoplasm of Lung
Neoplasms Pancreatic
Drug: Gemcitabine - 21 day cycle
Drug: Lomustine

The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV)...

Enrolling
Urinary Bladder Neoplasms
Drug: TAR-200
Radiation: Conventional radiation therapy

The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab...

Enrolling
Urinary Bladder Neoplasms
Biological: Cetrelimab
Drug: TAR-200

The goal of this clinical study is to compare the study drug, sacituzumab govitecan-hziy (SG), versus docetaxel in participants with advanced or meta...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Docetaxel
Biological: Sacituzumab Govitecan-hziy (SG)

Trial sponsors

Janssen logo

Janssen (2 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems